Skip to content


You're viewing the new version of our site. Please leave us feedback.

Learn more

BMC Cancer

Open Access
Open Peer Review

This article has Open Peer Review reports available.

How does Open Peer Review work?

Analysis of SLX4/FANCP in non-BRCA1/2-mutated breast cancer families

  • Juana Fernández-Rodríguez1,
  • Francisco Quiles1,
  • Ignacio Blanco1,
  • Alex Teulé1,
  • Lídia Feliubadaló1,
  • Jesús del Valle1,
  • Mónica Salinas1,
  • Àngel Izquierdo2,
  • Esther Darder2,
  • Detlev Schindler3,
  • Gabriel Capellá1,
  • Joan Brunet2,
  • Conxi Lázaro1Email author and
  • Miguel Angel Pujana4Email author
Contributed equally
BMC Cancer201212:84

Received: 13 September 2011

Accepted: 8 March 2012

Published: 8 March 2012

Back to article

Open Peer Review reports

Pre-publication versions of this article and author comments to reviewers are available by contacting

Original Submission
13 Sep 2011 Submitted Original manuscript
8 Nov 2011 Reviewed Reviewer Report - Manuel R Teixeira
15 Nov 2011 Reviewed Reviewer Report - Jordi Surralles
7 Dec 2011 Author responded Author comments - Miguel Angel Pujana
Resubmission - Version 2
7 Dec 2011 Submitted Manuscript version 2
23 Jan 2012 Reviewed Reviewer Report - Jordi Surralles
Resubmission - Version 3
Submitted Manuscript version 3
8 Mar 2012 Editorially accepted
8 Mar 2012 Article published 10.1186/1471-2407-12-84

How does Open Peer Review work?

Open peer review is a system where authors know who the reviewers are, and the reviewers know who the authors are. If the manuscript is accepted, the named reviewer reports are published alongside the article. Pre-publication versions of the article and author comments to reviewers are available by contacting All previous versions of the manuscript and all author responses to the reviewers are also available.

You can find further information about the peer review system here.

Authors’ Affiliations

Hereditary Cancer Program, Catalan Institute of Oncology (ICO), Hospital Duran i Reynals, Bellvitge Institute for Biomedical Research (IDIBELL), L'Hospitalet
Hereditary Cancer Program, ICO, Hospital Josep Trueta, Girona Biomedical Research Institute (IdIBGi)
Department of Human Genetics, University of Würzburg
Translational Research Laboratory, Biomedical Research Center Network for Epidemiology and Public Health (CIBERESP), ICO, IDIBELL, L'Hospitalet